98%
921
2 minutes
20
Background: Desensitization and blockade of 5-HT2C receptors (5-HT2CR) have long been thought to be central in the therapeutic action of antidepressant drugs. However, besides behavioral pharmacology studies, there is little in vivo data documenting antidepressant-induced 5-HT2CR desensitization in specific brain areas.
Methods: Mice lacking the 5-HT reuptake carrier (5-HTT(-/-)) were used to model the consequences of chronic 5-HT reuptake inhibition with antidepressant drugs. The effect of this mutation on 5-HT2CR was evaluated at the behavioral (social interaction, novelty-suppressed feeding, and 5-HT2CR-induced hypolocomotion tests), the neurochemical, and the cellular (RT-qPCR, mRNA editing, and c-fos-induced expression) levels.
Results: Although 5-HTT(-/-) mice had an anxiogenic profile in the novelty-suppressed feeding test, they displayed less 5-HT2CR-mediated anxiety in response to the agonist m-chlorophenylpiperazine in the social interaction test. In addition, 5-HT2CR-mediated inhibition of a stress-induced increase in 5-HT turnover, measured in various brain areas, was markedly reduced in 5-HTT(-/-) mutants. These indices of tolerance to 5-HT2CR stimulation were associated neither with altered levels of 5-HT2CR protein and mRNA nor with changes in pre-mRNA editing in the frontal cortex. However, basal c-fos mRNA production in cells expressing 5-HT2CR was higher in 5-HTT(-/-) mutants, suggesting an altered basal activity of these cells following sustained 5-HT reuptake carrier inactivation. Furthermore, the increased c-fos mRNA expression in 5-HT2CR-like immune-positive cortical cells observed in wild-type mice treated acutely with the 5-HT2CR agonist RO-60,0175 was absent in 5-HTT(-/-) mutants.
Conclusions: Such blunted responsiveness of the 5-HT2CR system, observed at the cell signaling level, probably contributes to the moderation of the anxiety phenotype in 5-HTT(-/-) mice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360241 | PMC |
http://dx.doi.org/10.1093/ijnp/pyu056 | DOI Listing |
Mikrochim Acta
September 2025
Affordable and Sustainable Sample Preparation (AS2P) Research Group, Departamento de Química Analítica, Instituto Químico para la Energía y el Medioambiente IQUEMA, Universidad de Córdoba, Campus Universitario de Rabanales, Edificio Marie Curie, E-14071, Córdoba, Spain.
Stainless-steel substrates have grown in importance in the development of planar sorptive phases. However, the reduced wettability of polished sheets makes difficult their functionalization. This limitation can be solved by using amorphous silica gel microparticles as superficial guides.
View Article and Find Full Text PDFNeuropsychopharmacology
September 2025
Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland.
Chronic treatment with fluoxetine, a widely prescribed selective serotonin reuptake inhibitor (SSRI), is known to promote neural plasticity. The role of fluoxetine in plasticity has been particularly tied to parvalbumin-positive interneurons, a key population of GABAergic neurons that regulate inhibitory tone and network stability. While our previous studies have highlighted fluoxetine-induced plasticity in the visual cortex and hippocampus, its cell-type-specific effects in the prefrontal cortex (PFC) remain unclear.
View Article and Find Full Text PDFCureus
August 2025
Psychiatry, Rashid Hospital, Dubai Health, Dubai, ARE.
Moyamoya disease (MMD) is a rare and progressive cerebrovascular disorder characterized by stenosis of the internal carotid arteries and their major branches, leading to the development of abnormal collateral vessels. While MMD is traditionally associated with ischemic and hemorrhagic strokes, there is increasing recognition of the psychiatric symptoms that can accompany the disease, which significantly impact patient outcomes and complicate management. This case report presents a 30-year-old female with a history of recurrent ischemic strokes, hypertension, diabetes, and dyslipidemia, who initially presented with neurological symptoms including headache, left-sided weakness, and facial deviation.
View Article and Find Full Text PDFIndian J Psychiatry
August 2025
Department of Psychiatry, Institute of Psychiatry-Centre of Excellence, Kolkata, West Bengal, India.
Supratherapeutic dosing of selective serotonin reuptake inhibitors (SSRIs) in obsessive-compulsive disorder (OCD) is an area of clinical interest, particularly for treatment-resistant cases. Standard SSRI doses often provide insufficient symptom relief, prompting clinicians to explore higher-than-recommended doses. Evidence suggests that supratherapeutic dosing can enhance serotonergic activity, potentially improving treatment response.
View Article and Find Full Text PDFFront Neurol
August 2025
Nuffield Department of Clinical Neurosciences, Oxford University Centre For Integrative Neuroimaging, Oxford, United Kingdom.
Introduction: Amblyopia is a neurodevelopmental visual disorder treated with occlusion or pharmacological penalization of the dominant, non-amblyopic eye in early childhood. After early childhood, efficacy of occlusion therapy is limited due to a reduction in neuronal plasticity, and no mainstay clinical treatment is available. Selective serotonin reuptake inhibitors (SSRIs) have been hypothesized to enhance neuroplasticity in the adult brain, thereby facilitating improvements in amblyopia.
View Article and Find Full Text PDF